5-MeO-MiPT, also known as moxy, is a synthetic tryptamine with a methoxy group at the 5-position of the indole ring and methyl-isopropyl substitution on the terminal nitrogen. It has appeared in recreational drug markets since the early 2000s and has been identified in clinical and forensic investigations. Research has examined its metabolism, acute effects in animals and a small number of human intoxication cases.
Chemistry and identification
5-MeO-MiPT is 5-methoxy-N-methyl-N-isopropyltryptamine. It differs from 5-MeO-DiPT by replacing one isopropyl group with a methyl group, and from 5-MeO-DMT by replacing one methyl group with an isopropyl group. These changes affect the compound’s pharmacological profile and metabolism.
Pharmacology
5-MeO-MiPT is a serotonergic compound with activity at 5-HT2A and other serotonin receptors. A 2024 preclinical study examined its effects on sensorimotor processing, motor activity, thermoregulation and cardiorespiratory measures in mice. The compound produced dose-dependent changes in sensorimotor responses and, at high experimental exposures, affected motor and cardiorespiratory measures (Bassi and colleagues, 2024).
Reported effects
User reports describe changes in visual perception, colour intensity, tactile sensation and mood. Other accounts mention nausea, gastrointestinal discomfort, anxiety, muscle tension and sleep disruption. These varying anecdotes cannot establish a controlled clinical account of its effects.
Metabolism and forensic findings
A 2018 study examined a confirmed intoxication case and used pooled human liver microsomes, blood and urine to identify metabolites. The proposed pathways included N-deisopropylation, N-demethylation, O-demethylation and hydroxylation. 5-MeO-NIPT and 5-OH-MiPT were among the metabolites identified across the biological samples (Grafinger and colleagues, 2018).
The 2024 paper examined the clinical background alongside animal experiments and in-silico ADMET predictions. It emphasised that human metabolism and toxicology data remain limited, despite the availability of some real-case analytical findings.
Early clinical development
In 2025, Mindstate Design Labs announced Phase I results for MSD-001, an oral formulation of 5-MeO-MiPT. The sponsor reported a favourable short-term tolerability profile and no serious adverse events, while describing a narrower psychoactive profile than that of classic psychedelics. These were company-reported results; independent assessment will require a full peer-reviewed clinical publication (Mindstate Design Labs, 2025).
Toxicity and research limitations
Clinical evidence is still too limited to define the acute toxic range, dependence potential or long-term effects of 5-MeO-MiPT. Isolated intoxication reports and animal studies indicate that it can affect perception, behaviour and physiological function, but they do not provide a reliable concentration-toxicity relationship.
Related tryptamines
5-MeO-MiPT is related to 5-MeO-DiPT, 5-MeO-DMT, 4-HO-MiPT and 4-AcO-MiPT. Its 5-methoxy group and methyl-isopropyl side chain distinguish it from the 4-substituted analogues.
